{"id":"db75e0d6-c386-5760-8a83-bb1b23dc3ace","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-migraine-adult-trial","predicate":"reduced_attacks_in_adult_trial","statement":"A55-person adult migraine trial found lower attack frequency and headache days with riboflavin than placebo.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"9b3c5a84-05cd-55cf-8444-2b3122a4312d","mechanism_event_label":"A small adult trial found preventive benefit; it did not establish that migraine is a B2-deficiency disease.","subject":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"object":{"id":"b7c15223-a4df-5d22-806a-01d8bc86b2a9","slug":"migraine-attack-frequency","display_name":"Migraine attack frequency","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"9b3c5a84-05cd-55cf-8444-2b3122a4312d","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-migraine-adult-trial-event","event_type":"observed_intervention","label":"A small adult trial found preventive benefit; it did not establish that migraine is a B2-deficiency disease.","description":"A55-person adult migraine trial found lower attack frequency and headache days with riboflavin than placebo.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b7c15223-a4df-5d22-806a-01d8bc86b2a9","slug":"migraine-attack-frequency","display_name":"Migraine attack frequency","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Double-blind placebo-controlled trial in 55 migraine patients; intention-to-treat analysis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"400 mg/day riboflavin or placebo for three months; pharmacological exposure.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Pharmacological dose, small sample and no direct mitochondrial mechanism measurement; prevention rather than acute pain relief.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Riboflavin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A small adult trial found preventive benefit; it did not establish that migraine is a B2-deficiency disease.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b2-schoenen1998] Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial (1998). https://pubmed.ncbi.nlm.nih.gov/9484373/ DOI: 10.1212/wnl.50.2.466","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Adults with migraine","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"e40fb7ea-5276-5a95-80ba-03aafc39cf44","evidence_kind":"source_excerpt","locator":"Lines 1717-1727","start_line":1717,"end_line":1727,"excerpt":"### b2-migraine-adult-trial\nA55-person adult migraine trial found lower attack frequency and headache days with riboflavin than placebo.\nCondition category: normal\nnutrient_topic: Riboflavin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A small adult trial found preventive benefit; it did not establish that migraine is a B2-deficiency disease.\norganism: Homo sapiens\ntissue_or_cell_type: Adults with migraine\nexperimental_model: Double-blind placebo-controlled trial in 55 migraine patients; intention-to-treat analysis.\nlimitations: Pharmacological dose, small sample and no direct mitochondrial mechanism measurement; prevention rather than acute pain relief.\nexposure: 400 mg/day riboflavin or placebo for three months; pharmacological exposure.\n[b2-schoenen1998] Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial (1998). https://pubmed.ncbi.nlm.nih.gov/9484373/ DOI: 10.1212/wnl.50.2.466","model_system":"Double-blind placebo-controlled trial in 55 migraine patients; intention-to-treat analysis.","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b2-schoenen1998] Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial (1998). https://pubmed.ncbi.nlm.nih.gov/9484373/ DOI: 10.1212/wnl.50.2.466","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"4f7c9578-82bf-5e2d-b5c4-72a79fb4f6af","stable_key":"import-548ab9d6-3a9b-5bed-879c-17d03813b636","title":"Riboflavin: mechanisms, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"680cb6bc8249877f2410f551807f10d390fdd719014137d7414ba3420e29228d","revision_id":"7a61e299-908d-5372-860b-99ed190f9d7a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}